JPMorgan Chase & Co. Sells 58,655 Shares of Kura Oncology, Inc. $KURA

JPMorgan Chase & Co. reduced its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 63.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 34,036 shares of the company’s stock after selling 58,655 shares during the period. JPMorgan Chase & Co.’s holdings in Kura Oncology were worth $301,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Rhumbline Advisers lifted its stake in shares of Kura Oncology by 0.9% during the 3rd quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after acquiring an additional 1,039 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Kura Oncology by 11.1% during the 3rd quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock worth $220,000 after acquiring an additional 2,478 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Kura Oncology by 15.8% during the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock worth $181,000 after acquiring an additional 2,802 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Kura Oncology by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock worth $175,000 after acquiring an additional 2,976 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after acquiring an additional 2,977 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on KURA shares. Leerink Partners set a $20.00 price target on Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Mizuho decreased their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th. Wall Street Zen lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Finally, Lake Street Capital initiated coverage on Kura Oncology in a research report on Tuesday. They set a “buy” rating and a $23.00 target price for the company. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $26.38.

Kura Oncology Trading Down 1.0%

Shares of NASDAQ KURA opened at $9.05 on Thursday. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $8.48 and a two-hundred day simple moving average of $9.51. The firm has a market cap of $803.28 million, a PE ratio of -2.85 and a beta of 0.25. Kura Oncology, Inc. has a twelve month low of $5.45 and a twelve month high of $12.49.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). The firm had revenue of $17.34 million for the quarter, compared to the consensus estimate of $34.71 million. Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. Analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 7,142 shares of the business’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the completion of the transaction, the senior vice president directly owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. The trade was a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Teresa Brophy Bair sold 11,208 shares of the business’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the transaction, the insider directly owned 226,931 shares of the company’s stock, valued at approximately $1,919,836.26. The trade was a 4.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 36,068 shares of company stock valued at $305,135. Company insiders own 6.40% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.